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Inhibition of dipeptidyl peptidase IV (DPP-IV) may be exploited to maintain the incretin 
effect during the postprandial phase. As a result, glycemic regulation and energy homeo-
stasis may be improved. Food protein-derived peptides have been identified as natural 
agents capable of inhibiting DPP-IV. Ile-Pro-Ile is the most potent DPP-IV inhibitory pep-
tide identified to date. A minimum analog peptide set approach was used to study pep-
tide analogs of Ile-Pro-Ile. The DPP-IV half maximal inhibitory concentration (IC50) values 
of the 25 peptides evaluated ranged from 3.9 ± 1.0 µM (Ile-Pro-Ile) to 247.0 ± 32.7 µM 
(Phe-Pro-Phe). The presence of Pro at position 2 of tripeptides was required to achieve 
high DPP-IV inhibition. Most peptides behaved as competitive inhibitors of DPP-IV with 
the exception of peptides with a N-terminal Trp, which were mixed-type inhibitors. While 
possessing the structure of preferred DPP-IV substrates, most peptides studied were 
particularly stable during 30 min incubation with DPP-IV. Molecular docking revealed that 
Ile-Pro-Ile and its peptide analogs interacted in a very similar manner with the active site 
of DPP-IV. In addition, no correlation was found between the Hydropathic INTeraction 
score and the DPP-IV IC50 values of the peptides studied. This outcome suggests that 
free energy may not be directly responsible for enzyme inhibition by the peptides. Finally, 
novel DPP-IV inhibitory peptides were identified using the strategy employed herein. 
These results may be relevant for the development of food protein-derived peptides with 
serum glucose lowering and food intake regulatory properties in humans.
Keywords: dipeptidyl peptidase iV inhibition, ile-Pro-ile (diprotin a), bioactive peptides, peptide analogs, design of 
experiments, quantitative structure activity relationship, molecular docking
inTrODUcTiOn
The inhibition of dipeptidyl peptidase IV (DPP-IV) is one of the numerous therapeutic strategies 
used for the management of type 2 diabetes. DPP-IV can cleave incretins such as glucagon-like 
peptide-1 (GLP-1) and glucose inhibitory polypeptide, resulting in a loss of their insulinotropic 
activity during the postprandial phase. The inhibition of DPP-IV has been shown to result in a better 
regulation of glycemia in type 2 diabetic subjects (1, 2). For this reason, several DPP-IV inhibitory 
drugs, known as gliptins, have been developed as antidiabetic agents (1). In addition, GLP-1 has 
been shown to modulate energy homeostasis by slowing down gastric emptying, inducing satiety, 
and reducing food intake (3).
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Food proteins also contain peptide sequences, which are able 
to inhibit DPP-IV in vitro, in cell cultures and in small animals 
[for reviews, see Ref. (4, 5)]. Therefore, food protein-derived pep-
tides may have an effect on the regulation of glucose metabolism 
in vivo. Food protein hydrolyzates have often been characterized 
for their DPP-IV inhibitory potency by quantifying their half 
maximal inhibitory concentration (IC50). Food protein-derived 
hydrolyzates are generally ~104 times less potent than gliptins (6). 
However, food and drug interventions may be complimentary in 
the management of type 2 diabetes (7). In fact, combinations of 
gliptins and hydrolyzates can have additive effects in terms of 
their ability to inhibit DPP-IV (6).
To date, the most potent DPP-IV inhibitory peptides reported 
in the literature are Ile-Pro-Ile and Val-Pro-Leu, also known as 
diprotin A and B, respectively. Their DPP-IV IC50 value is 3.5 and 
15.8 µM, respectively (8). Both peptides were originally isolated 
from Bacillus cereus cultures (8). However, Ile-Pro-Ile and Val-
Pro-Leu are also present in the primary sequence of several food 
proteins (9). The details of particularly potent DPP-IV inhibitory 
peptides displaying IC50 values <  100  µM have recently been 
reviewed (5). Ile-Pro-Ile and Val-Pro-Leu were, respectively, 
shown to be >12 and 2 times more potent than other food 
protein-derived peptides. In addition, only nine other tripeptides 
having DPP-IV IC50 values < 100 µM have been identified to date 
(Table S1 in Supplementary Material). Interestingly, all these 
tripeptides possess a Pro at position 2. This suggests that peptides 
having the structure Xaa1-Pro-Xaa3 (with Xaa an amino acid 
residue), may be of interest in studying those properties, which 
dictate the potency of DPP-IV inhibitory peptides. Furthermore, 
Pro-containing peptides have been reported to be particularly 
resistant to gastrointestinal digestion and potentially bioavailable 
as demonstrated by their detection in the gastrointestinal tract 
and in the circulation of humans [for reviews, see Ref. (10–12)].
Analogs of lead drug compounds are often used in drug 
discovery to design molecules with higher activity, improved bio-
availability, or reduced side effects (13). DPP-IV inhibitory pep-
tide analogs possessing the structure Trp-Arg-Xaa were studied 
using a peptide library of the 20 possible peptides (14). The most 
potent peptide discovered using this approach was Trp-Arg-Glu 
having a DPP-IV IC50 value of 350 µM. However, the utilization 
of a peptide library strategy to study Xaa1-Pro-Xaa3 would involve 
the analysis of 400 peptides (20 × 20 amino acids for Xaa1 and 
Xaa3). Therefore, in order to reduce the number of peptides for 
analysis, the concept of minimum analog peptide set (MAPS) 
has been introduced (15, 16). MAPS has been described during 
the study of peptide analogs employed for the development of 
meaningful quantitative structure activity relationship (QSAR) 
models for angiotensin converting enzyme (ACE) inhibition. 
MAPS correspond to specific peptide sets containing a minimum 
number of sequences, which are chosen by factorial or fractional 
factorial design to incorporate physicochemical properties rel-
evant for a target bioactivity. To date, MAPS has been employed 
in the prediction of oxytocin (oxytocic and pressor activity), pep-
statin (inhibition of porcine pepsin), and bradykinin (bradykinin 
potentiating) analogs (16). MAPS approaches do not appear to 
have been widely employed for the study of food protein-derived 
bioactive peptides.
The aim of this study was, therefore, to apply a MAPS-based 
approach to design peptide analogs of Ile-Pro-Ile. This was 
achieved by developing a QSAR model for DPP-IV inhibitory 
peptides to better understand the physicochemical characteris-
tics, which are relevant to DPP-IV inhibition. In a second stage, 
a factorial design was employed to design the peptide analogs. 
The peptides were then assessed for their in vitro DPP-IV inhibi-
tory properties and their mode of inhibition. Finally, molecular 
docking studies were conducted to better understand how those 
peptides may interact with the active site of DPP-IV.
MaTerials anD MeThODs
reagents
High-performance liquid chromatography (HPLC) grade water 
was from VWR (Dublin, Ireland). Trifluoroacetic acid, formic 
acid (FA), tris(hydroxymethyl)aminomethane (Tris), Gly-Pro-
pNA, diprotin A (Ile-Pro-Ile), porcine DPP-IV (≥10  U  mg−1 
protein), mass spectrometry (MS) grade water, and acetonitrile 
were purchased from Sigma Aldrich (Dublin, Ireland). Synthetic 
peptides (Ala-Ile-Pro, Ala-Pro-Ala, Ala-Pro-Phe, Ala-Pro-Arg, 
Ala-Arg-Pro, Ile-Phe-Lys, Ile-Ile-Phe, Ile-Pro-Ala, Ile-Arg-Phe, 
Ile-Arg-Lys, Lys-Pro-Ala, Lys-Arg-Ile, Arg-Ile-Phe, Arg-Ile-Arg, 
Arg-Lys-Arg, Phe-Pro-Phe, Phe-Pro-Ile, Phe-Pro-Trp, Ile-Ala-
Ile, Ile-Pro-Phe, Ile-Pro-Trp, Trp-Pro-Phe, Trp-Pro-Ile, Trp-Pro-
Trp) with a purity > 95% (w/w) were obtained from Genscript 
(Piscataway, NJ, USA).
Qsar Modeling
The QSAR analysis linking the DPP-IV IC50 value of peptides to 
their physicochemical properties was conducted using a partial 
least squares regression (PLSR) model (Eq.  1) as previously 
described (17). The peptides used (Table 1) were all competitive 
inhibitors of DPP-IV, and their IC50 values were obtained using 
the same DPP-IV inhibition assay (18). These conditions were 
selected given that it was previously demonstrated that this was 
required in order to obtain a significant PLSR model (17). The 
structural v-scale [v1 (van der Waals volume), v2 (net charge 
index), and v3 (hydrophobic parameter of side chains)] from Lin 
et al. (19) was employed for the amino acid descriptors. Peptide 
descriptors for the two N- and C-terminal amino acids of the 
sequences were generated to take account of peptides with vari-
ous lengths (2–9 amino acids, Table 1) as described earlier (20). 
The PLSR model employed is described in Eq. 1
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(1)
with Y: the Log10(DPP-IV IC50); i: the N- or C- terminal position 
of the amino acid (1 or 2); j: the amino acid descriptor number 
(varying between 1 and 3); a and b: the coefficients of the model; 
c, and ε the constant and residual of the model, respectively.
Generation of the peptide descriptors and PLSR model was 
carried out using Matlab (version R2015b, MathWorks, Inc., 
Natick, MA, USA). Training and test sets comprising 28 and 5 
peptides, respectively, were randomly chosen (100 times) by the 
Matlab algorithm in order to cross validate the PLSR model.
Table 1 | Dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration 
(IC50) of competitive inhibitory peptides used in the quantitative structure activity 
relationship model.
Peptide sequencea length DPP-iV ic50 (μM) reference
IPI 3 3.5 (21)
IPIQY 5 35.2 (21)
WL 2 43.6 (22)
LPVPQ 5 43.7 (17)
FLQP 4 65.3 (23)
IPM 3 79.4 (17)
LPVP 4 87.0 (24)
MPVQA 5 93.3 (24)
LPYPY 5 108.3 (21)
HL 2 143.2 (18)
IP 2 149.6 (21)
VA 2 168.2 (18)
LLQLEAIR 8 177.8 (24)
YPYY 4 194.4 (21)
LPQNIPPLT 9 205.2 (17)
VPGEIVE 7 224.5 (17)
LPL 3 241.4 (21)
YPY 3 243.7 (21)
LPLPL 5 325.0 (21)
LPLPLL 6 371.5 (17)
FL 2 399.6 (18)
IPSK 4 406.8 (17)
VLGP 4 580.4 (23)
RP 2 657.2 (17)
YP 2 658.1 (21)
LP 2 712.5 (21)
ILELA 5 721.1 (24)
AL 2 882.1 (18)
LW 2 993.4 (22)
QPLPPT 6 1,013.8 (17)
SL 2 2,517.1 (18)
GL 2 2,615.0 (18)
EK 2 3,216.8 (18)
aPeptide sequences abbreviated with the one letter amino acid code. Peptides are 
ordered by decreasing DPP-IV inhibitory potency.
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experimental Design for the selection  
of Peptide analogs of ile-Pro-ile
All the Ile-Pro-Ile analogs used had a fixed length of three amino 
acids. In addition, the QSAR model used herein, as well as a previ-
ous QSAR model (17), highlighted the importance of the amino 
acid hydrophobicity in the inhibition of DPP-IV. Therefore, a 
factorial design consisting of 3 factors at 2 levels was employed 
to design peptide analogs of Ile-Pro-Ile. Each factor represented 
a position within the peptide sequence (Xaa1, Xaa2, and Xaa3, 
where Xaai designates the amino acid located at position i of 
the peptide) and each level corresponded to a low (−1) or high 
(+1) hydrophobicity parameter of side chains (v3) for the amino 
acid. The 15 conditions of the factorial design corresponding to 
the hydrophobicity of the selected peptides (Ala-Ile-Pro, Ala-
Pro-Ala, Ala-Pro-Phe, Ala-Pro-Arg, Ala-Arg-Pro, Ile-Phe-Lys, 
Ile-Ile-Phe, Ile-Pro-Ala, Ile-Arg-Phe, Ile-Arg-Lys, Lys-Pro-Ala, 
Lys-Arg-Ile, Arg-Ile-Phe, Arg-Ile-Arg, and Arg-Lys-Arg), are 
presented in Table 2.
The experimental values obtained with the 15 peptides were 
used to develop a predictive multilinear regression (MLR) model 
linking the % DPP-IV inhibition obtained at 500 µM with the v3 
values of the amino acids contained in the peptides. The MLR is 
described in Eq. 2
 
%DPP IV inhibition− = + + + + +
+ + + +
β β β β β β
β β β
0 1 2 3 4
2
5
2
6
2
7 8
x y z x y
z xy xz β9yz + ε  (2)
with β0 to β9: the coefficients of the model; x, y, and z, the z-centered 
parameters for the v3 values of Xaa1, Xaa2, and Xaa3, respectively; 
ε: the residual of the model.
Equation 2 was used to predict the structures of nine tripep-
tides potentially displaying high DPP-IV inhibition at 500 µM.
DPP-iV inhibition assay and Mode  
of inhibition
Peptides were dispersed in HPLC grade water at 50 and 500 µM 
(final concentration). The DPP-IV inhibition assay was carried 
out in triplicate as outlined by Nongonierma and FitzGerald 
(18). Briefly, samples (25  μL) were mixed with Gly-Pro-pNA 
(final concentration 0.200  mM) and DPP-IV (final concentra-
tion 0.0025 U mL−1) in a 96-well microplate (Sarstedt, Dublin, 
Ireland). The microplate was incubated at 37°C for 60 min in a 
microplate reader (Biotek Synergy HT, Winooski, VT, USA) and 
absorbance was monitored at 405 nm.
Dose–response curves were determined for peptides display-
ing a percentage of inhibition > 50% at 500 µM. Peptides were 
diluted in HPLC water at concentrations ranging from 0.37 
to 500  µM (final concentration). The DPP-IV IC50 values were 
determined by plotting the percentage inhibition as a function of 
the test compound concentration. Each analysis was carried out 
in triplicate (n = 3).
The mode of DPP-IV inhibition was determined using the 
Lineweaver and Burke double reciprocal representation as previ-
ously described (18). The most potent DPP-IV inhibitory pep-
tides (i.e., Ala-Pro-Ala, Ala-Pro-Phe, Ala-Pro-Arg, Ile-Pro-Ala, 
Lys-Pro-Ala, Phe-Pro-Phe, Phe-Pro-Ile, Phe-Pro-Trp, Ile-Pro-
Phe, Ile-Pro-Trp, Trp-Pro-Phe, Trp-Pro-Ile, Trp-Pro-Trp) were 
assayed at three different final concentrations corresponding to 
their IC50 value divided by 4, 8, and 16. The peptide solution was 
substituted with 100 mM Tris–HCl buffer pH 8.0 in the negative 
control. Gly-Pro-pNA was added at concentrations ranging from 
0.1 to 0.6 mM (final concentration). The absorbance at 405 nm 
was recorded for 30 min at 37°C using a microplate reader (Biotek 
Synergy HT). Each sample was evaluated four times.
stability of Peptides to DPP-iV
Stability of the peptides to hydrolysis by DPP-IV was evaluated 
by liquid chromatography tandem mass spectrometry (LC-MS/
MS) using the samples generated during the Lineweaver and 
Burk analysis containing DPP-IV inhibitory peptides at their 
IC50 values divided by 4 as previously described (24). Following 
the 30 min reaction, DPP-IV was heat inactivated by immers-
ing samples in a water bath set at 90°C for 20 min. Test samples 
were subsequently diluted 40 times in mobile phase A (0.1% 
FA in MS water). Intact peptides were analyzed at the same 
concentration as the test samples. The peptide composition 
of the samples was determined as described previously (25). 
Table 2 | Dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50), z-centered value of the hydrophobic parameter of side chains [v3 in the scale 
developed by Lin et al. (19)] of the amino acids constitutive of the peptides, and mode of inhibition of peptide analog of Ile-Pro-Ile.
set number Peptide sequencea z-centered values ofv3 of 
the amino acids within the 
tripeptide
Predicted  
DPP-iV ic50 (μM)
experimental  
DPP-iV ic50 (μM)
Mode of  
inhibition
Peptide hydrolyzed 
by DPP-iV
Xaa1 Xaa2 Xaa3
1 IPI 0.725 0.059 0.725 238 3.9 ± 1.0 Competitive NO
AIP −0.194 0.725 0.059 103 nd nd nd
APA −0.194 0.059 −0.194 988 44.3 ± 3.2 Competitive NO
APF −0.194 0.059 0.716 168 65.8 ± 5.5 Competitive NO
APR −0.194 0.059 −1.000 15 119.7 ± 3.5 Competitive NO
ARP −0.194 −1.000 0.059 687 nd nd nd
IFK 0.725 0.716 −0.991 34 nd nd nd
IIF 0.725 0.725 0.716 71 nd nd nd
IPA 0.725 0.059 −0.194 472 28.3 ± 3.4 Competitive NO
IRF 0.725 −1.000 0.716 476 nd nd nd
IRK 0.725 −1.000 −0.991 107 nd nd nd
KPA −0.991 0.059 −0.194 22,690 74.5 ± 7.0 Competitive NO
KRI −0.991 −1.000 0.725 67,699 nd nd nd
RIF −1.000 0.725 0.716 7,435 nd nd nd
RIR −1.000 0.725 −1.000 662 nd nd nd
RKR −1.000 −0.991 −1.000 2,451 nd nd nd
2 FPF 0.716 0.059 0.716 177 247.0 ± 32.7 Competitive YES
FPI 0.716 0.059 0.725 524 45.2 ± 5.3 Competitive NO
FPW 0.716 0.059 1.000 67 54.9 ± 2.9 Competitive YES
IAI 0.725 −0.194 0.725 97 nd nd nd
IPF 0.725 0.059 0.716 80 47.3 ± 12.3 Competitive YES
IPW 0.725 0.059 1.000 31 175.3 ± 5.5 Competitive YES
WPF 1.000 0.059 0.716 214 159.8 ± 12.8 Mixed-type YES
WPI 1.000 0.059 0.725 633 133.0 ± 14.7 Mixed-type NO
WPW 1.000 0.059 1.000 81 120.1 ± 13.1 Mixed-type YES
aPeptide sequences abbreviated with the one letter amino acid code. The first set corresponds to Ile-Pro-Ile and its 15 associated peptide analogs. The second set corresponds to 
Ile-Ala-Ile and the eight additional peptides tested, which possess the Xaa1-Pro-Xaa3 structure, with Xaa1 and Xaa3 being Ile, Phe, or Trp.
nd, not determined; IC50, DPP-IV half maximal inhibitory concentration; NO, peptide not cleaved during incubation with DPP-IV; YES, peptide cleaved following incubation  
with DPP-IV.
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Briefly, an ultra-high performance liquid chromatography 
(UHPLC) UltiMate 3000 (Dionex, Camberley, Surrey, UK) 
fitted with a security guard UHPLC C18 PEPTIDE (2.1 mm, 
Phenomenex, Cheshire, UK) and an Aeris Peptide XB-C18 
column (150 mm × 2.1 mm, 1.7 µm, Phenomenex) was used 
for peptide separation at 25°C. A sample volume of 2 µL was 
injected with a solvent delay of 4 min. The UHPLC was coupled 
to a quadrupole time-of-flight mass spectrometer (Q-TOF, 
Impact HD™, Bruker Daltonics GmbH, Bremen, Germany) 
using a 50–600 m/z acquisition range. The MS was fitted with 
an electrospray ionization source used in positive ion mode. 
Data acquisition was performed with Hystar software (Bruker 
Daltonics). Data analysis was performed with Compass Data 
Analysis 4.2 (Bruker Daltonics).
Molecular Docking of Peptides  
to the active site of DPP-iV
Interactions between the most potent DPP-IV inhibitory peptides 
and the active site of DPP-IV were investigated using molecular 
modeling. This analysis was based on docking simulations 
coupled with rescoring procedures to predict protein–peptide 
interactions and pharmacophoric analyses to investigate the 
hydrophobic/hydrophilic properties of the binding site.
The molecular model for porcine DPP-IV was derived from 
the crystallographic structure deposited in the RCSB Protein Data 
Bank1 having the PDB code 1ORW (26). The protein and peptides 
analyzed were processed using the Sybyl software, version 8.12 
checking the consistency of atom and bond type assignment. The 
co-crystallized ligands were removed before proceeding with the 
analysis.
Specifically, the coupling of GOLD, as docking software, and 
Hydropathic INTeraction (HINT) (27) as rescoring function, 
was chosen. This was done on the basis of previous studies (i) 
demonstrating the high reliability of HINT in predicting ligand 
interactions with several protein targets (28), (ii) estimating the 
free energy of protein–ligand complex formation (29), and (iii) 
estimating enzyme inhibitory activity of small molecules and 
peptides (30, 31). In particular, the HINT score provides an 
empirical and quantitative evaluation of protein–ligand interac-
tion as a sum of all single atomic contributions. The HINT score 
correlates with the free energy of binding. Therefore, the higher 
the HINT score, the more favorable the protein–ligand interac-
tion. The software settings and the docking protocol reported 
1 http://www.rcsb.org (Accessed: January 27, 2018).
2 www.certara.com (Accessed: February 26, 2017).
Table 3 | Statistical significance of the partial least squares regression linking 
the dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50) 
of the peptides used to generate the quantitative structure activity relationship 
model.
Parameter value
n 33
R2 model 0.66
p model 0.01
Root mean square error 0.45
F 3.16
R2 cross validation 0.57
p lack of fit 0.15
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by Dellafiora et al. (31) were used. Briefly, the protein was kept 
semi-flexible with the polar hydrogens set free to rotate, while 
ligands were set to be fully flexible. The maximum number of 
poses generated for each ligand was set at 25, and all the poses 
underwent a rescoring procedure with the HINT scoring func-
tion. Only the pose with the highest HINT score was kept for each 
ligand as it was considered to be the most favorable.
The pharmacophoric analysis of the ligand binding site was 
carried out using the Flapsite tool of the FLAP (Fingerprint for 
Ligand and Protein) software developed by Molecular Discovery 
Ltd.3 (32). The GRID algorithm was used to investigate the cor-
responding pharmacophoric space (33). The DRY probe was 
used to describe potential hydrophobic interactions, while the sp2 
carbonyl oxygen (O) and the neutral flat amino (N1) probes were 
used to describe the hydrogen bond acceptor and donor capacity 
of the target, respectively. All images were obtained using the 
PyMol software version 2.0.4
statistical analysis
The significance of the PLSR used in the QSAR modeling (Eq. 1) 
was assessed using p model, p lack of fit, R2 and R2 cross validation 
as previously described (17). All statistical analyses were carried 
out with Matlab.
resUlTs
Qsar Model for DPP-iV inhibitory 
Peptides
A total of 33 competitive DPP-IV inhibitory peptides were 
employed to build the PLSR model (Eq.  1; Table  1). The 
experimentally determined DPP-IV IC50 values of these peptides 
varied between 3.5 and 3,216.8 µM for Ile-Pro-Ile and Glu-Lys, 
respectively. The PLSR analysis linking the DPP-IV IC50 value 
to the amino acid descriptors of the peptides was statistically 
significant with a p model and p lack of fit value of 0.01 and 
0.15, respectively (Table 3). The coefficients of the PLSR model, 
which were significant (p < 0.05) were the constant (c), a1,3 and 
b2,3 (Figure  1A). This indicated that the hydrophobicity of the 
amino acids located at the N-terminal and next to the C-terminal 
positions of peptides were important for the DPP-IV inhibitory 
potency of peptides. The relationship (R2 and R2 cross validation 
0.66 and 0.57, respectively, Table 3) between the predicted and 
experimental DPP-IV IC50 value of the peptides used to build the 
QSAR model (Table 1) is illustrated on Figure 1B.
DPP-iV inhibitory Properties of Peptide 
analogs of ile-Pro-ile
Peptide analogs of Ile-Pro-Ile were designed by varying the 
hydrophobicity of the constitutive amino acids of the tripeptide 
following a design of experiments (DOE, Table 2). The % DPP-IV 
inhibition of the 15 tripeptides when evaluated at 500 µM varied 
depending on the peptide sequence (Figure 2A). Some peptides 
(Ala-Ile-Pro, Ala-Arg-Pro, Ile-Phe-Lys, Ile-Ile-Phe, Lys-Arg-Ile, 
3 http://www.moldiscovery.com (Accessed: January 8, 2017).
4 http://www.pymol.org (Accessed: March 6, 2017).
Arg-Ile-Phe, and Arg-Ile-Arg) were not able to inhibit DPP-IV 
at 500 µM. Arg-Lys-Arg, Ile-Arg-Lys, and Ile-Arg-Phe inhibited 
DPP-IV by less than 25%. The percentage of DPP-IV inhibition 
observed with the other peptides (Ile-Pro-Ile, Ala-Pro-Ala, 
Ala-Pro-Phe, Ala-Pro-Arg, Ile-Pro-Ala, and Lys-Pro-Ala) when 
evaluated at 500 µM was > 65% (Figure 2A).
Equation  2 was used to predict the % DPP-IV inhibition at 
500  µM of the 15 tripeptides from set #1. Two coefficients, β2 
and β5, which were associated with the hydrophobicity of the 
second amino acid of the tripeptides, were significant (p < 0.05, 
Figure 2B). Peptides with an Ala/Thr/His/Gly/Pro at position 2 
were predicted to yield high DPP-IV inhibition when evaluated 
at 500 µM. Pro at position 2 of peptides has been identified as a 
feature of potent tripeptides (5). Equation 2 predicted that eight 
tripeptides (Phe-Pro-Phe, Phe-Pro-Ile, Phe-Pro-Trp, Ile-Pro-Phe, 
Ile-Pro-Trp, Trp-Pro-Phe, Trp-Pro-Ile, and Trp-Pro-Trp), which 
had the Xaa1-Pro-Xaa3 structure and similar hydrophobicities 
as Ile-Pro-Ile would yield high DPP-IV inhibition at 500  µM. 
Ile-Ala-Ile was also evaluated as Ala has been described as being 
a preferred amino acid residue at position 2 in DPP-IV peptide 
substrates (Table 2). The % DPP-IV inhibition at 500 µM of these 
nine sequences (peptide set #2) is illustrated in Figure 2C. The % 
inhibition of DPP-IV for these nine sequences was predicted to 
be >99% using the MLR model (Figure 2C). However, Ile-Ala-Ile 
could only inhibit 9.6 ± 1.9% of DPP-IV activity when evaluated 
at 500 µM (Figure 2C). As this peptide was not potent, it was not 
further evaluated. The % inhibition of DPP-IV by the eight other 
tripeptides from set #2 varied between 62.9 ± 10.1 and 90.1 ± 1.8% 
for Phe-Pro-Phe and Phe-Pro-Ile, respectively (Figure 2C).
The IC50 values of the most potent peptides, which inhibited 
DPP-IV by >50% at 500  µM, were determined (Table  2). The 
QSAR model predicted and the experimentally determined 
DPP-IV IC50 values of the peptides are shown in Table  2. The 
DPP-IV IC50 values of the peptides varied between 3.9 ± 1.0 and 
247.0 ±  32.7  µM for Ile-Pro-Ile and Phe-Pro-Phe, respectively 
(Table 2). The QSAR analysis predicted DPP-IV IC50 values for 
the peptides ranging from 15 to 67,699 µM for Ala-Pro-Arg and 
Lys-Arg-Ile, respectively (Table 2).
Mode of DPP-iV inhibition and stability  
of Peptides to DPP-iV
The mode of inhibition of DPP-IV was determined using 
Lineweaver and Burke double reciprocal plots (Figure 3). Most 
FigUre 1 | (a) Coefficients of the partial least squares regression (PLSR) linking the dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50) of 
the peptides used to generate the quantitative structure activity relationship (QSAR) model (Eq. 1). *Coefficients with a p < 0.05 are significantly different from 0.  
(b) Predicted DPP-IV IC50 value of the peptides used to build the QSAR model (Table 1) as a function of the experimental DPP-IV IC50 value, the line represents the 
QSAR model (Eq. 1).
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of the peptides studied in relation to their mode of inhibition 
(Ile-Pro-Ile, Ala-Pro-Ala, Ala-Pro-Phe, Ala-Pro-Arg, Ile-Pro-
Ala, Lys-Pro-Ala, Phe-Pro-Phe, Phe-Pro-Ile, Phe-Pro-Trp, 
Ile-Pro-Phe, and Ile-Pro-Trp) were competitive inhibitors of 
DPP-IV. However, three peptides (Trp-Pro-Phe, Trp-Pro-Ile, 
and Trp-Pro-Trp) were mixed-type inhibitors of DPP-IV 
(Table 2).
Peptide stability to DPP-IV was evaluated with the samples 
generated during the analysis of the mode of inhibition. Several 
peptides (Ile-Pro-Ile, Ala-Pro-Ala, Ala-Pro-Phe, Ala-Pro-Arg, 
Ile-Pro-Ala, Lys-Pro-Ala, Phe-Pro-Ile, and Trp-Pro-Ile) were 
not hydrolyzed by DPP-IV (Table 2; Figures 4A,C). Six peptides 
(Phe-Pro-Phe, Phe-Pro-Trp, Ile-Pro-Phe, Ile-Pro-Trp, Trp-Pro-
Phe, and Trp-Pro-Trp) were partly hydrolyzed by DPP-IV fol-
lowing cleavage at the C-terminal side of the Pro residue (Table 2; 
Figures 4B,D).
Molecular Modeling of DPP-iV binding 
interactions With Peptides
The geometry of binding of the most potent peptides within 
the DPP-IV binding site was investigated using molecular 
modeling based on pharmacophoric analysis and docking 
simulations coupled to rescoring procedures. The workflow 
used has already proved successful in computing the binding 
architecture of low-molecular mass ligands (34, 35). However, 
a fit-for-purpose validation was carried out to check the case-
specific reliability. To this end, the 3D structures of porcine 
DPP-IV bound with non-covalent competitive inhibitors, 
which are available in the RCSB PDB database (36) (see text 
footnote 1), were taken as validation reference. Specifically, four 
structures were found (database last accessed on January 25th 
2018). The chemical structures of the inhibitors are reported 
in Figure S1 in Supplementary Material. The 3D structures 
FigUre 2 | (a) Percentage of dipeptidyl peptidase IV (DPP-IV) inhibition observed with the peptides of the minimum analog peptide set evaluated at 500 µM. Values 
are mean ± SD (n = 3). (b) Coefficients of the model (β0–β9; Eq. 2) linking the % DPP-IV inhibition of the peptides at 500 µM to their hydrophobicity (v3).  
(c) Predicted vs. experimental % DPP-IV inhibition of peptides from set #1 (diamonds) and set #2 (squares) evaluated at 500 µM. The line represents the  
multilinear regression model determined with data from peptide set #1 (Eq. 2).
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of the inhibitors (1-methylamine-1-benzyl-cyclopentane, 
(S)-2-[(R)-3-amino-4-(2-fluoro-phenyl)-butyryl]-1,2,3,4-
tetrahydro-isoquinoline-3-carboxylic acid amide, 7-benzyl-
1,3-dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione 
and 8-[(3~{R})-3-azanylpiperidin-1-yl]-7-[(2-bromophenyl)methyl]- 
1,3-dimethyl-purine-2,6-dione) were retrieved from the PDB 
chemical component repository and underwent the docking 
simulation study and the rescoring procedures. As shown in 
Figure S2 in Supplementary Material, all the computed poses 
were in strong agreement with the crystallographic data support-
ing the case-specific reliability of the procedure in computing the 
binding architectures of the ligands.
In addition, a pharmacophoric analysis of the porcine DPP-
IV-binding site was carried out to map the space available for 
ligands in terms of hydrophobic and hydrophilic environment 
distributions. As shown in Figure  5, the ligand-binding sites 
showed an environment mainly able to receive hydrophobic and 
H-bond donor groups, with a limited space suitable for receiving 
H-bond acceptor groups. The binding architecture of the well-
known DPP-IV inhibitory peptide, Ile-Pro-Ile, was calculated 
along with that of the other DPP-IV inhibitory peptide analogs. 
As shown in Figures 6A,B, the computed architecture of Ile-Pro- 
Ile was found to be in strong agreement with the crystallographic 
pose observed within human DPP-IV (37). In particular, both 
the ligand arrangement and the polar interactions network 
computed by the procedure were found to be consistent with 
those reported in the crystallographic data currently available 
(Figures  6A,B). This result further confirmed the reliability 
of the procedure. In addition, the binding pose of Ile-Pro-Ile 
complied with the pharmacophoric requirements of the binding 
pocket as the two hydrophobic side chains of Ile were found to be 
arranged into the hydrophobic space available for ligands, while 
the C- and N-terminal groups were found to be arranged into 
regions suitable to receive H-bond acceptor and donor groups, 
respectively (Figure  7). All the other inhibitory peptides were 
found to adopt an architecture of binding comparable to Ile-Pro-
Ile. In addition, with other peptides, polar interactions between 
Arg125, Glu205, Glu206, and Tyr662 and Ile-Pro-Ile were also 
observed (Figure 6).
The binding site of porcine DPP-IV was compared to that of 
the human orthologous. The porcine and human enzymes have an 
identical length of 766 residues and the overall sequence identity 
is 88% (26) with a strongly conserved 3D organization (Figure 8). 
In relation to the catalytic site, those residues forming the space 
available for ligands showed 100% conservation in terms of 
residue composition and organization (Figure 8). Consequently, 
the pharmacophoric fingerprints of the two binding pockets were 
found to be highly comparable (Figure 8).
FigUre 3 | Lineweaver and Burke double reciprocal representation of (a) Ile-Pro-Ile (competitive), (b) Ala-Pro-Phe (competitive), (c) Ile-Pro-Trp (competitive), and 
(D) Trp-Pro-Trp (mixed-type) evaluated at their half maximal inhibitory concentration divided by 4, 8, and 16. Values are the mean reciprocal initial rate ± SD (n = 4).
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DiscUssiOn
The ability of Pro-containing tripeptides to inhibit DPP-IV in vitro 
was investigated. It has been suggested that Pro-containing pep-
tides are relatively stable to gastrointestinal enzymes (38). Specific 
Pro-containing tripeptides may also be bioavailable in humans. 
For instance, Ile-Pro-Pro and Val-Pro-Pro have been identified in 
human sera following the ingestion of a milk beverage enriched 
in lactotripeptides (39). Ile-Pro-Ile is the most potent DPP-IV 
inhibitory peptide identified to date in the literature (5). Therefore, 
a MAPS-based approach was employed herein to design peptide 
analogs of Ile-Pro-Ile with the view to (i) study the role of trip-
eptide structures on DPP-IV inhibition and (ii) identify novel 
potent inhibitors of DPP-IV. A range of in silico methodologies 
including DOE, QSAR modeling, and molecular docking were 
used to design and study peptide analogs of Ile-Pro-Ile.
Several structural and physicochemical parameters of 
molecules have been shown to affect their ability to inhibit 
DPP-IV (40). The hydrophobicity of amino acids located within 
specific positions of peptides is thought to be of importance for 
the inhibition of DPP-IV (9, 41, 42). The QSAR model (Eq. 1) 
demonstrated that the hydrophobicity (v3) of the amino acids at 
the N-terminal and next to the C-terminal positions of peptides 
played a role in their DPP-IV inhibitory properties (Figure 2A). 
For tripeptides, the hydrophobicity (v3) of the second amino acid 
was shown to be linked with DPP-IV inhibition by the peptides 
(Eq. 2; Figure 2B). The models (Eqs 1 and 2) developed here were 
all significant (p < 0.05). However, they had limitations in terms 
of their predictive ability for DPP-IV inhibitory properties of 
peptides (Table 2; Figure 2C). Similar results have been obtained 
during the development of a QSAR model, which showed differ-
ences between predicted and experimental DPP-IV IC50 values 
of peptides (17). Similarly, with other metabolic enzymes such 
as ACE, major differences between QSAR predicted and experi-
mental IC50 values have been reported for peptides on a number 
of occasions (43, 44). These differences are likely due to the fact 
that physicochemical parameters, other than those that are used 
to build the models, may play an important role in the inhibitory 
properties studied.
Other than hydrophobicity, aromaticity and steric hindrance 
of amino acid residues may play a role in the ability of peptides 
to inhibit DPP-IV. In a recent review paper on DPP-IV inhibi-
tory properties of molecules, Ojeda-Montes et al. (40) suggested 
that potent DPP-IV inhibitors included molecules possessing 
FigUre 4 | Stability of the peptides [concentration 1/4 of their half maximal inhibitory concentration (IC50)] during incubation with dipeptidyl peptidase IV (DPP-IV) 
and Gly-Pro-pNA for 30 min at 37°C in Tris–HCl buffer pH 8.0. Extracted ion chromatogram of the ultra-high performance liquid chromatography tandem mass 
spectrometry (MS/MS) of (a) Ile-Pro-Ile, (b) Ile-Pro-Trp, (c) Trp-Pro-Ile, and (D) Trp-Pro-Phe. peptide_std: peptide, which was not incubated with DPP-IV; GPpNA_
blank: Gly-Pro-pNA incubated with DPP-IV; peptides are abbreviated with the one letter amino acid code.
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aromatic rings, which can establish hydrophobic interactions 
with the S1 subsite of the DPP-IV active site. Earlier studies have 
reported on the existence of exclusion volumes in the S1 pocket of 
DPP-IV (45). These exclusion volumes may be responsible for the 
limited access of bulky amino acids residues to the active site of 
DPP-IV. This may prevent interactions between certain peptides 
and the active site of DPP-IV and/or the entry path to the catalytic 
site. Nevertheless, based on the molecular docking outcomes, all 
tripeptides studied herein were predicted to interact in a very 
similar manner with the active site of DPP-IV (Figure 6), and 
no evident steric interferences due to the aromatic or aliphatic 
residues in positions Xaa1 and Xaa3 were found. This finding is 
consistent with the availability of space to arrange side chains at 
positions #1 and #3 as both subsites are exposed to the bulk sol-
vent with a large capability to arrange sidechains reducing steric 
interferences. On the other side, the Xaa2 position is likely to be 
more affected by steric restraints being buried into the protein 
core with a limited capability to accept bulky side chains (Figure 
S3 in Supplementary Material). On this basis, the discrepancies 
between the calculated and experimental inhibitory activity of 
the peptides considered herein might be due to additional factors 
beyond the inherent capability to interact with the binding site. 
This may relate to the capability to go through the entry path of 
the binding site and/or the capability of peptide binding to induce 
molecular rearrangement of DPP-IV, which in turn may affect 
enzymatic activity.
The % DPP-IV inhibition at 500 µM measured with tripeptides 
from set #1 confirmed that the presence of a Pro at position 2 
was important to observe substantial inhibition of DPP-IV 
(Figures 2A,C). In fact, all tripeptides from sets #1 and 2, which 
possessed a Pro in position 2 inhibited DPP-IV while peptides pos-
sessing a different amino acid in position 2 were not able to inhibit 
DPP-IV or were not potent DPP-IV inhibitors (Figures  2A,C; 
Table 2). These results are consistent with earlier findings report-
ing on the features of potent (IC50 < 100 µM) DPP-IV inhibitory 
tripeptides, which also revealed the occurrence of a Pro residue 
at position 2 (5). Other analogs of Ile-Pro-Ile have been shown 
earlier to be relatively potent inhibitors of DPP-IV (Table S1 in 
Supplementary Material). For instance, Ile-Pro-Ala, also known 
as β-lactosin A (an antihypertensive peptide), had previously 
FigUre 5 | The biological assembly of the porcine dipeptidyl peptidase IV (DPP-IV) (PDB ID 1ORW) (26) is represented in cartoon on the right side, while a close up 
of pharmacophoric environment of the binding site is represented on the left. The yellow mesh retraces the shape of the binding site, while the white, blue, and red 
contours identify regions sterically and energetically favorable for hydrophobic, hydrogen bond donor and hydrogen bond acceptor groups, respectively.
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been reported for its ability to inhibit DPP-IV (46). The DPP-IV 
IC50 value of Ile-Pro-Ala reported herein was slightly lower 
than that reported by Tulipano et al. (46), i.e., 28.3 (Table 2) vs. 
49.0 µM. However, this was consistent with the DPP-IV IC50 value 
of Ile-Pro-Ile, which was 3.9 vs. 7 µM (46). Several novel peptides 
displaying a DPP-IV IC50 value < 100 µM (Ala-Pro-Ala, Ala-Pro-
Phe, Lys-Pro-Ala, Phe-Pro-Ile, Phe-Pro-Trp, and Ile-Pro-Trp, 
Table 2) were reported herein for the first time. The presence of a 
Pro residue at position 2 has often been associated with DPP-IV 
inhibition. However, it is not a guarantee for high DPP-IV inhibi-
tory potency (Table 2; Table S1 in Supplementary Material). The 
amino acids located at the N- and C-terminal side of tripeptides 
also appear to play an important role in their DPP-IV inhibitory 
properties. This can be seen with the variation in the DPP-IV IC50 
value of peptides differing in either their N- or C-terminal amino 
acid (Table 2).
Ile-Pro-Ile possesses the structure of preferred DPP-IV 
inhibitory substrates. Incubation of Ile-Pro-Ile with DPP-IV was 
reported to induce its breakdown over time. For instance, after 
36 min incubation, 37% of the initial amount of Ile-Pro-Ile was 
cleaved by DPP-IV (47). These results are in contrast with our 
findings, showing no hydrolysis of Ile-Pro-Ile following 30 min 
incubation with DPP-IV, which is consistent with earlier reports 
(21, 24). Other tripeptides (Ala-Pro-Ala, Ala-Pro-Phe, Ala-Pro-
Arg, Ile-Pro-Ala, Lys-Pro-Ala, Phe-Pro-Ile, and Trp-Pro-Ile) 
studied herein, which possess the structure of preferred DPP-IV 
inhibitory substrates, were also not hydrolyzed by DPP-IV after 
30  min incubation (Table  2; Figure  4). In contrast, Phe-Pro-
Phe, Phe-Pro-Trp, Ile-Pro-Phe, Ile-Pro-Trp, Trp-Pro-Phe, and 
Trp-Pro-Trp were partly hydrolyzed by DPP-IV during 30 min 
incubation. Substrate-type inhibitors are generally susceptible 
to hydrolysis by the enzyme (48). Several milk protein-derived 
peptides with a penultimate Pro have been shown to be degraded 
during incubation with DPP-IV (21, 49, 50). An earlier study has 
demonstrated that the extent of cleavage of peptides possessing 
the structure of DPP-IV substrates depended on the enzyme to 
substrate ratio (E:S) and the peptide sequence (21). A higher E:S 
generally resulted in higher extents of peptide cleavage. This may 
explain the differences seen in the extent of cleavage of Ile-Pro-
Ile between the study from Rahfeld et  al. (47) and our results. 
Surprisingly, Ile-Ala-Ile, which also possesses the structure of 
preferred DPP-IV substrates, could not significantly inhibit 
DPP-IV (<10% DPP-IV inhibition at 500 µM). Further investiga-
tion is warranted to explain this result.
As expected, most peptides with a Pro at position 2 were able to 
bind the active site of DPP-IV as demonstrated by their competi-
tive mode of inhibition (Table 2). However, peptides possessing 
a Trp at their N-terminal position, i.e., Trp-Pro-Phe, Trp-Pro-Ile, 
and Trp-Pro-Trp were mixed-type inhibitors of DPP-IV. Several 
peptides having a Trp residue at their N-terminal position 
have been shown to be non-competitive inhibitors of DPP-IV 
(18, 22, 51). It has been suggested in earlier studies that alternative 
binding sites, differing from the active site of DPP-IV exist. The 
outcomes of molecular docking studies suggested that a number 
of peptides with a Trp N-terminus can bind secondary sites of 
DPP-IV. The location of this secondary binding site is nearby the 
active site of DPP-IV (51, 52). Pro-Phe, Trp-Pro-Ile, and Trp-
Pro-Trp possess the structure of preferred substrates of DPP-IV 
(i.e., Pro residue at position 2). This is further confirmed by 
the fact that Trp-Pro-Phe and Trp-Pro-Trp were hydrolyzed by 
DPP-IV (Table 2). The mixed mode of inhibition of the peptides 
studied herein may arise from the fact that Trp-Pro-Phe, Trp-Pro-
Ile, and Trp-Pro-Trp are also able to bind both to the active and 
secondary sites of DPP-IV.
FigUre 6 | Binding architectures of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides. The protein is represented in cartoon while peptides and amino acid side 
chains are represented in sticks. Yellow dotted lines indicate the protein–peptide polar interactions. (a) Ile-Pro-Ile. (b) Crystallographic pose of Ile-Pro-Ile within 
human DPP-IV [PDB structure 1WCY (37)]. (c) Trp-Pro-Phe. (D) Ala-Pro-Ala. (e) Ale-Pro-Phe. (F) Ala-Pro-Arg. (g) Phe-Pro-Phe. (h) Ile-Pro-Ala. (i) Lys-Pro-Ala.  
(J) Phe-Pro-Ile. (K) Phe-Pro-Trp. (l) Ile-Pro-Phe. (M) Trp-Pro-Ile. (n) Ile-Pro-Trp. (O) Trp-Pro-Trp.
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Molecular docking showed that Ile-Pro-Ile and its associated 
peptide analogs established similar interactions with the active 
site of porcine DPP-IV (Figure  6). These interactions are con-
sistent with those (i.e., with Glu205, Glu206, Tyr662) that have 
been demonstrated earlier with the S1 pocket of the active site 
of DPP-IV (40). Nevertheless, there was no correlation between 
the computed scores and the experimentally determined DPP-IV 
IC50 values (Figure 6; Table 2). Bearing in mind that the HINT 
score correlates with the free energy of binding (29), this result 
might suggest that the energy of interaction within the catalytic 
site of DPP-IV may have a secondary role in determining inhibi-
tion of the enzyme. This may particularly be the case here since 
FigUre 8 | Structural and pharmacophorical comparison between porcine [PDB ID 1ORW (26)] and human [PDB ID 1WCY (37)] dipeptidyl peptidase IV (DPP-IV). 
Proteins are represented in cartoon while amino acids constitutive of the binding site are represented in sticks. The white, blue, and red meshes identify regions 
sterically and energetically favorable for hydrophobic, hydrogen bond donor and hydrogen bond acceptor groups, respectively.
FigUre 7 | Calculated binding pose of Ile-Pro-Ile within the active site of porcine dipeptidyl peptidase IV (DPP-IV). The protein is represented in cartoon, while the 
amino acids constitutive of the binding site (yellow) and Ile-Pro-Ile (white) are shown in sticks. The white, blue, and red meshes identify regions sterically and 
energetically favorable for hydrophobic, hydrogen bond donor and hydrogen bond acceptor groups, respectively. The proper placement of the Ile-Pro-Ile groups in 
respect to the pharmacophoric requirements of the pocket is highlighted with rings. Specifically, gray indicates hydrophobic regions, while red and blue indicate 
regions suitable to receive hydrogen bond acceptor and donor groups, respectively.
12
Nongonierma et al. DPP-IV Inhibition of Ile-Pro-Ile Analogs
Frontiers in Endocrinology | www.frontiersin.org June 2018 | Volume 9 | Article 329
the peptides also possess the structure of preferred DPP-IV sub-
strates and, therefore, the mechanisms of inhibition may be more 
complex than a simple binding of peptides to the active site. This 
hypothesis is further supported by the unexpected stability of 
the peptides during incubation with DPP-IV (Table 2; Figure 4). 
It appears that the manner in which peptides bind to the active 
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site of DPP-IV may protect them from extensive degradation. 
It is interesting to note that all peptides cleaved by DPP-IV 
possess bulky amino acid residues (i.e., Trp and Phe) at their 
C-terminal side.
The results herein are relevant to glycemic regulation and 
potentially food intake in humans. This is particularly the case 
as the study herein reports on potent DPP-IV inhibitory peptides 
(Ile-Pro-Ile and Ile-Pro-Ala) having the characteristics of pep-
tides, which have previously been shown to be relatively stable 
to gastrointestinal enzymes (53, 54). Several of these peptides 
were also shown to be relatively stable to DPP-IV (Table  2; 
Figure 4). Therefore, they may be resistant to the action of brush 
border DPP-IV in the intestine and protect incretins from early 
degradation by DPP-IV. There was 100% conservation for the 
composition and organization of residues forming the space 
available for ligands within the crystal structures of porcine and 
human DPP-IV (Figure  8). Therefore, it may be assumed that 
peptides able to interact with the porcine DPP-IV active site may 
also interact with that of the human ortholog. As a consequence, 
inhibition of human DPP-IV activity may be expected for the 
most potent peptides studied herein. Nonetheless, due to the 
non-conserved residues at other regions in DPP-IV, effects in 
reaching the binding site and/or in regulating the protein dynam-
ics, and the reaction kinetics cannot be excluded. Accordingly, 
differences in the magnitude of the inhibition between the two 
orthologous may occur. In this regard, it is worth mentioning, 
however, that short peptides (<5 residues) have been shown to 
inhibit human and porcine DPP-IV in a similar manner (55). The 
ability of peptide analogs of Ile-Pro-Ile to play a role as DPP-IV 
inhibitors in humans needs to be evaluated during human inter-
vention studies.
In recent studies, the utilization of Pro-rich protein substrates 
has been employed as a strategy to develop relatively potent 
DPP-IV inhibitory hydrolyzates. The 1  kDa permeate of an 
ultrafiltration fraction from a porcine skin gelatin hydrolyzate 
had a DPP-IV IC50 value of 1.50 mg mL−1 (56). Salmon gelatin 
hydrolyzates having DPP-IV IC50 values between 0.08 ±  0.01 
and 0.71  ±  0.09  mg  mL−1 have been reported (57). Wheat 
gluten hydrolyzates, which are also rich in Pro-containing 
peptides, had DPP-IV IC50 values of 0.136 (58) and 0.24 ± 0.02 
to 0.66 ± 0.06 mg mL−1 (59). Food (milk, porcine skin gelatin, 
and wheat gluten) hydrolyzates were shown to contain numerous 
tripeptides with a Pro at position 2, some of which had DPP-IV 
IC50 values <  100  µM (53, 54, 56, 58–61). While the effects of 
these hydrolyzates in humans have not been evaluated, they may 
represent natural alternatives to synthetic drugs for glycemic 
regulation.
cOnclUsiOn
Within this work, the utilization of MAPS has been described 
for the study of analogs of Ile-Pro-Ile, the most potent DPP-IV 
inhibitory peptide identified to date. While relatively potent 
DPP-IV inhibitory peptides were identified, none were as potent 
as Ile-Pro-Ile. This study has confirmed the importance of a Pro 
residue in position 2 of tripeptides in displaying potent DPP-IV 
inhibitory properties. Molecular docking showed very similar 
interactions between Ile-Pro-Ile and its associated peptide ana-
logs. However, the HINT scores did not correlate with the DPP-IV 
IC50 values obtained experimentally. This result, together with 
the surprisingly high stability of Ile-Pro-Ile and its associated 
peptide analogs to the hydrolytic action of DPP-IV suggests that 
complex mechanisms are involved in the inhibition of DPP-IV 
by these peptides. The peptides investigated in this study may 
have potential applications for glycemic management and energy 
homeostasis in humans.
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